Bio Medica Laboratories Ltd (BMLL) — shareholding pattern, promoter holding, financials and share price
About Bio Medica Laboratories Ltd (BMLL)
Bio Medica Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BMLL and on the BSE under scrip code 95758. Its ISIN is INE1BKA01015.
Incorporated in August 2015, Bio Medica Laboratories Ltd specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the -counter (OTC) medications [1]
Listed peers in Pharmaceuticals: Sanjivani Paranteral Ltd, Accretion Pharmaceuticals Ltd, Parnax Lab Ltd, Panchsheel Organics Ltd, Speciality Medicines Ltd, Auro Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹130 a share on 10 Jul 2026, Bio Medica Laboratories Ltd (BMLL) was valued at a price-to-earnings ratio of 17.3x against an industry P/E of 36.41x and a price-to-book of 2.64x on a book value of ₹49.24 per share. Solomo computes return on equity of 66.48% and return on capital employed of 47.7% from filed results.
- P/E
- 17.3x
- Industry P/E
- 36.41x
- P/B
- 2.64x
- Book value / share
- ₹49.24
- ROE
- 66.48%
- ROCE
- 47.7%
- Debt / equity
- 1.02x
- Dividend yield
- 0%
- 52-week range
- ₹101.5 – ₹148
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Bio Medica Laboratories Ltd (BMLL) reported revenue of ₹38.2 crore, net profit of ₹9.79 crore and earnings per share of ₹10.66. That compares with revenue of ₹15.25 crore and net profit of ₹2.5 crore in Mar 2024. Figures are standalone, as filed with the exchanges.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue (₹ cr) | 16.23 | 15.25 | 38.2 |
| Net profit (₹ cr) | 0.33 | 2.5 | 9.79 |
| EPS (₹) | 33 | 250 | 10.66 |
| Measure | 1Y |
|---|---|
| Sales growth | 150.49% |
| Profit growth | 291.60% |